An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine pancreatic cancer
- 12 April 2024
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 718, 149931
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (32171468, 82273843, JCYJ20210324121814039)
This publication has 16 references indexed in Scilit:
- Therapy with oncolytic viruses: progress and challengesNature Reviews Clinical Oncology, 2023
- The emerging field of oncolytic virus-based cancer immunotherapyTrends in Cancer, 2022
- A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastomaNature Communications, 2022
- An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situMolecular Therapy, 2022
- NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cellsCell Reports, 2021
- Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal AdenocarcinomaMolecular Therapy, 2021
- Pancreatic cancerThe Lancet, 2020
- Immunotherapy for pancreatic cancer: A 2020 updateCancer Treatment Reviews, 2020
- Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species–mediated DNA damageNature Immunology, 2019
- Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cellsCellular Signalling, 2014